The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
CSF biomarker variability in the Alzheimer's Association quality control program
Open accessAbstract
Background: The cerebrospinal fluid (CSF) biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease (AD) research and patient management. However, there are large variations in biomarker measurements among and within laboratories. Methods: Data from the first nine rounds of the Alzheimer's Association quality control program was used to define the extent and sources of analytical variability. In each round, three CSF samples prepared at the Clinical Neurochemistry Laboratory (Mölndal, Sweden) were analyzed by single‐analyte enzyme‐linked immunosorbent assay (ELISA), a multiplexing xMAP assay, or an immunoassay with electrochemoluminescence detection. Results: A total of 84 laboratories participated. Coefficients of variation (CVs) between laboratories were around 20% to 30%; within‐run CVs, less than 5% to 10%; and longitudinal within‐laboratory CVs, 5% to 19%. Interestingly, longitudinal within‐laboratory CV differed between biomarkers at individual laboratories, suggesting that a component of it was assay dependent. Variability between kit lots and between laboratories both had a major influence on amyloid beta 1–42 measurements, but for total tau and phosphorylated tau, between‐kit lot effects were much less than between‐laboratory effects. Despite the measurement variability, the between‐laboratory consistency in classification of samples (using prehoc‐derived cutoffs for AD) was high (>90% in 15 of 18 samples for ELISA and in 12 of 18 samples for xMAP). Conclusions: The overall variability remains too high to allow assignment of universal biomarker cutoff values for a specific intended use. Each laboratory must ensure longitudinal stability in its measurements and use internally qualified cutoff levels. Further standardization of laboratory procedures and improvement of kit performance will likely increase the usefulness of CSF AD biomarkers for researchers and clinicians.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“The majority of the participants use INNOTEST enzyme-linked immunosorbent assays (ELISAs; n 5 61 in round 9) or bead-based xMAP platforms with the INNO-BIA AlzBio3 (both Innogenetics, Gent, Belgium; www.innogenetics. com; n 5 12 in round 9) to quantify Ab42, T-tau and P-tau (181P) (or simply P-tau).”
BackgroundSelf-citationAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · cited 1×
“The majority of the participants use INNOTEST enzyme-linked immunosorbent assays (ELISAs; n 5 61 in round 9) or bead-based xMAP platforms with the INNO-BIA AlzBio3 (both Innogenetics, Gent, Belgium; www.innogenetics. com; n 5 12 in round 9) to quantify Ab42, T-tau and P-tau (181P) (or simply P-tau).”
BackgroundSelf-citationBlennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Self-citationReduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., Van de Voorde, A., Martin, J., & Cras, P. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb09823.x · Cited by 495
Self-citationOlsson, A., Vanderstichele, H., Andreasen, N., De Meyer, G., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 437
Self-citation
Cited by
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Self-citationAdvancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPreclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
Self-citation
Metadata
- Authors
- Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., Robin Hsiung, G., Hyman, B., Iqbal, K., Lachno, D. R., Lleó, A., Lewczuk, P., Molinuevo, J. L., Parchi, P., Regeniter, A., Rissman, R., Rosenmann, H., Sancesario, G., Schröder, J., Shaw, L. M., Teunissen, C. E., Trojanowski, J. Q., Vanderstichele, H., Vandijck, M., Verbeek, M. M., Zetterberg, H., Blennow, K., Käser, S. A., Alzheimer's Association QC Program Work Group, Rojo, A. J. A., Albert, M., Alcolea, D., Andreasson, U., Antonell, A., Arai, H., Archetti, S., Arkblad, E., Baldeiras, I., Bartos, A., Batish, D., Bedel, A., Bentue‐Ferrer, D., Berisha, F., Bernardini, S., Blankenstein, M., Blennow, K., Bousiges, O., Camuso, M. C., Carrillo, M., Casoli, T., Cavallaro, S., Chalbot, S., Collins, S., Cruz e Silva, O., Cutler, N., Cuvelier, I., Delaroche, O., Dufour‐Rainfray, D., Dyer, R., Engelborghs, S., Fagan, A. M., Fogli, A., Forlenza, O. V., Fox, N., Frisoni, G., Galimberti, D., Galloni, E., Gritti, S., Gylys, K. H., Hampel, H., Haustein, S., Heath, T., Heegaard, N. H. H., Heneka, M. T., Herukka, S., Holtzman, D., Hsiung, G. R., Humpel, C., Hyman, B., Iwatsubo, T., Iqbal, K., Jardel, C., Jucker, M., Kapaki, E., Käser, S. A., Kidd, D., Klivenyi, P., Kuwano, R., Lachno, D. R., Lamari, F., Laplanche, J., Laser, J., Lehmann, S., Lewczuk, P., Li, Q., Lleó, A., Maetzler, W., Malaplate‐Armand, C., Martin, R., Martone, R. L., Masters, C., Mattsson, N., Mercken, M., Molinuevo, J. L., Montine, T., Nowatzke, W., Otto, M., Parchi, P., Parent, X., Parnetti, L., Persson, S., Petersen, R., Poesen, K., Quadrio, I., Quillard, M., Regeniter, A., Rello, V. L., Rissman, R., Rohan, Z., Rosenmann, H., Sancesario, G., Schröder, J., Shaw, L. M., Sisowath, C., Skinningsrud, A., Soares, H., Soininen, H., Søndersø, K. C., Spreer, A., Suardi, S., Teunissen, C., Trojanowski, J. Q., Umek, R., Van Broeck, B., Vandenberghe, R., Vanderstichele, H., Vandijck, M., Vecsei, L., Verbeek, M., Vostiar, I., Windisch, M., & Zetterberg, H.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2013-05
- Volume
- 9
- Issue
- 3
- Pages
- 251-261
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2130983640
- Cited by
- 382
- References
- 29
- FWCI
- 26.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CSF biomarker variability in the Alzheimer's Association quality control program. https://app.cochat.ai/papers/10.1016/j.jalz.2013.01.010
- The paper
- Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., Robin Hsiung, G., Hyman, B., Iqbal, K., Lachno, D. R., Lleó, A., Lewczuk, P., Molinuevo, J. L., Parchi, P., Regeniter, A., . . . Zetterberg, H. (2013). CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.01.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.